R&D News | pharmaphorum

News

J&J abandons Alzheimer's antibody in setback for tau

Hopes that anti-tau drugs could emerge as treatments for Alzheimer's have been dented by the failure of a phase 2b trial of J&J's posdinemab.

News

Neuralink rival Paradromics cleared to start speech trial

Brain computer interface developer Paradromics has been cleared to start a US clinical trial of its Connexus implant for speech restoration.

News

ADC specialist Solve raises $120m, and other biofinancings

Our round-up of biofinancings is led by a $120m round for ADC specialist Solve, with Aspen, Artios, Profluent, and Gate Bioscience also raising funds.

News

Merck partners Valo on $3bn, AI-based Parkinson's project

Merck has teamed up with Valo Health on a project to apply AI to the discovery of novel drug targets and drugs for Parkinson's.

News

Agios shares slump on sickle cell disease data

Shares in Agios lost nearly half their value after it posted mixed clinical results from a phase 3 trial of its sickle cell disease therapy mitapivat.

News

US vulnerable to China's API dominance, says report

China has such a dominant position in pharmaceutical ingredient production that there is a risk it will weaponise access, says a Congressional report.

J&J abandons Alzheimer's antibody in setback for tau

Neuralink rival Paradromics cleared to start speech trial

ADC specialist Solve raises $120m, and other biofinancings

Merck partners Valo on $3bn, AI-based Parkinson's project

Agios shares slump on sickle cell disease data

US vulnerable to China's API dominance, says report

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks